Vandetanib for Thyroid Cancer

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Genzyme, a Sanofi Company

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.

Eligibility Criteria

This trial is for people with advanced or metastatic hereditary or sporadic medullary thyroid cancer that can't be removed by surgery. Participants must have tumors that can be measured and should be able to take oral medication. They shouldn't have had major surgery, chemotherapy, radiation therapy (except palliative care), or treatment with ZD6474 recently.

Inclusion Criteria

My thyroid cancer cannot be removed by surgery and has spread.

My tumor can be measured.

Exclusion Criteria

I have not had major surgery in the last 4 weeks.

I have been treated with ZD6474 before.

I haven't had radiation therapy in the last 4 weeks, except for palliative care.

I received my last chemotherapy dose less than 4 weeks ago.

I have had major heart problems.

Treatment Details

The study tests the effects of ZD6474 (Vandetanib) on patients with medullary thyroid cancer. It aims to understand how patients respond to the drug, its side effects, how it's processed in the body, and if it can slow down or stop tumor growth.

2Treatment groups

Experimental Treatment

Active Control

Group I: 2Experimental Treatment1 Intervention

Vandetanib

Group II: 1Active Control1 Intervention

Placebo vandetanib